▶ TESOFENSINE · SUBTOPIC · MECHANISM
TESOFENSINE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Triple monoamine reuptake inhibitor blocking norepinephrine, dopamine, and serotonin transporters (NET, DAT, SERT). Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease; off-target weight-loss signal discovered in early trials. Saniona currently developing for obesity and Prader-Willi syndrome.
PHARMACOKINETIC HALF-LIFE
Reported half-life for TESOFENSINE: ~9 days. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
TESOFENSINE is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Monoamine reuptake inhibitors block the presynaptic transporters that clear norepinephrine (NET), dopamine (DAT), and serotonin (SERT) from the synaptic cleft, prolonging neurotransmission. The class spans selective single-transporter inhibitors and triple reuptake inhibitors. Tesofensine is a triple monoamine reuptake inhibitor originally developed for Parkinson's and Alzheimer's disease; the Phase 2 obesity signal was discovered as an off-target effect and is the basis for ongoing weight-management trials.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (GH-axis reference). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
TIPO-1 (Astrup 2008, PMID 18950853) reported -12.8 kg LS mean weight loss at 1.0 mg vs -2.2 kg placebo at 24 weeks. n=203.
TIPO-1 reported small dose-dependent increase in heart rate and blood pressure. Manageable in further development.
Saniona TES-PWS and TES-HO Phase 3 programs ongoing in Prader-Willi and hypothalamic obesity.
MECHANISM Q+A
▶ What is tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor that blocks the norepinephrine, dopamine, and serotonin transporters (NET, DAT, SERT). Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease; the weight-loss signal was discovered as an off-target effect and is the basis for ongoing Phase 3 obesity programs.
▶ Tesofensine vs GLP-3 · which is stronger?
Different mechanisms. Tesofensine acts on central monoamine pathways; GLP-3 is a GLP-1 receptor agonist. TIPO-1 Phase 2 reported -12.8 kg at 24 weeks with tesofensine 1.0 mg, comparable to STEP-1 GLP-3 2.4 mg results at similar timepoints. Direct head-to-head not available.
▶ What is the half-life of tesofensine?
Approximately 9 days. Long half-life enables once-daily dosing with steady-state plasma levels after 4-5 weeks of treatment.
▶ How does tesofensine cause weight loss?
Central monoamine reuptake inhibition increases synaptic norepinephrine, dopamine, and serotonin in hypothalamic appetite-regulating circuits. The combined effect suppresses appetite and increases energy expenditure. Different mechanism from incretin or melanocortin-targeting compounds.
▶ What were the cardiovascular signals?
TIPO-1 reported dose-dependent increases in heart rate (~7 bpm at 1.0 mg) and modest blood pressure increases. The signal is manageable in further development but limits the dose ceiling and excludes patients with significant cardiovascular disease.
CITED LITERATURE
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008. PMID 18950853. link
- Bello NT, Zahner MR. Tesofensine: A novel weight-loss agent for obesity treatment. Drug Discov Today Ther Strateg 2009. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25